跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-ARIPIPRAZOLE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-ARIPIPRAZOLE
Authorized
STANDARD
MINT-ARIPIPRAZOLE
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e0bd6f0ff9586b0c
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
e0bd6f0ff9586b0c
Drug Approval Canada Name
MINT-ARIPIPRAZOLE
Product Name
MINT-ARIPIPRAZOLE
Status
Marketed
Status Date
2020-04-14
Original Market Date
2020-04-14
Din
02483602
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:16.08.04
Atc Original
N05AX12 ARIPIPRAZOLE
Atc Name
n 05 ax 12
Aig Number
0152514005
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
ARIPIPRAZOLE
30 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e0bd6f0ff9586b0c
Type
Standard
Back to Health Canada Approvals